Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate.
New Delhi [India], October 21 (ANI/SRV): Surat Hematology Centre, one of the leading Hematology centres in Surat, recently celebrated a landmark achievement of the 50th successful Bone Marrow Transplant. The Centre specialises in Bone Marrow Transplants and the treatment of blood disorders in the South Gujarat region and has some of the best Hematologists in Surat as their founders. The centre has achieved this remarkable feat in a very short period of time. The centre was established by two visionaries sharing the same passion, Dr Hasmukh R Balar and Dr Dharmesh Vaghasiya, both being Hemato-Oncologist & BMT Physicians. They started their journey with the 1st Autologous BMT (Bone Marrow Transplant) centre in the entire South Gujarat region. Steadily gaining a foothold in Autologous BMT, the natural progression led to their first successful Allogeneic BMT with a matched related donor in February 2020 and by September 2020, they were onto the 1st Haplo-matched BMT. By now the Surat H
QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology molecule, tigilanol tiglate in combination with MSD's immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) for patients with unresectable melanoma, the deadliest form of skin cancer.